First and upfront, let’s call this virus WARS*, which stands for Wuhan Associated Respiratory Syndrome. President Xi Jingping called for a war against the new virus, and a war it is. Therefore our acronym makes intuitive sense. The naming of Continue reading Some Thoughts about the New Coronavirus Syndrome and its Transmission
Besides ceftriaxone (CTRIAX), cefixime and spectinomycin we have no other highly effective single-dose treatment regimens for urogenital GC. Failures of all 3 drugs have been described but remain rare, can be overcome with higher doses of CTRIAX (1 g instead Continue reading GC Therapy – Shooting for the Stars
The WHO just released the latest statistics on what has turned into the largest ever outbreak of Ebola virus (EBOV) in Africa. The epidemic started in Guinea around December 2013. As of 7/27/2014, Guinea, Liberia, Nigeria, and Sierra Leone have reported Continue reading Ebola – Fact Sheet (Updated 10/3/2014)
It was clear from the outset that the new roster of HCV drugs would change the playing field. Gilead’s NS5B polymerase inhibitor sofosbuvir and J&J’s NS3/4A protease inhibitor simeprevir have already revolutionized the treatment paradigm, pushing telaprevir and boceprevir, the Continue reading So Many HCV “Guidelines”: Can’t We Wait Till the Dust Has Settled?